Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Status:
Recruiting
Trial end date:
2031-10-30
Target enrollment:
Participant gender:
Summary
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except
T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Under the condition of full
course of PD-1/PD-L1 blockades, patients who achieved both radiological and biological
complete response after 3 cycles of platinum-based chemotherapy plus PD-1/PD-L1 blockades
will be randomized in a 1:1:1 ratio to receive reduced-dose radiotherapy (60Gy/30F) alone or
reduced-dose radiotherapy plus concurrent chemotherapy or standard dose radiotherapy
(70Gy/33F) with concurrent chemotherapy. To solve the urgent problem of whether patients with
high-risk advanced nasopharyngeal carcinoma are suitable for downgrade treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University First Affiliated Hospital, Sun Yat-Sen University Guangdong Provincial People's Hospital Hunan Cancer Hospital Second Affiliated Hospital, Sun Yat-Sen University The fifth Affiliated Hospital of Guangzhou Medcial University Tongji Hospital Zhongshan People's Hospital, Guangdong, China